Combination therapy with venetoclax and azacitidine for the treatment of myelodysplastic syndromes with < em > DDX41 < /em > mutations

In this study, we evaluated the efficacy of venetoclax and azacitidine combination therapy in eight consecutive MDS patients with DDX41 mutations at our centre from March 2021 to November 2023. We retrospectively analyzed the genetic features and clinical characteristics of these patients. Our findings suggest that MDS patients with DDX41 mutation may benefit from the therapy, for six subjects received this regimen as initial therapy and five of the six subjects achieved complete remission.PMID:38597818 | DOI:10.1080/16078454.2024.2338509

Source: Hematology - April 10, 2024 Category: Hematology Authors: Xin Wang Zhijian Xiao Tiejun Qin Zefeng Xu Yujiao Jia Shiqiang Qu Bing Li Lijuan Pan Qingyan Gao Meng Jiao Robert Peter Gale Source Type: research